Cost analysis of ganirelix versus luteal-phase lupron downregulation per assisted reproductive technology (ART) cycle and pregnancy achieved

Abstract

Both luteal-phase lupron downregulation (luteal lupron) and ganirelix have been shown to be efficacious in preventing a luteinizing hormone (LH) surge in ART cycles. Based on the work of the North American Ganirelix Group, ganirelix has been shown to be safe and effective with a reduction in the number of injections, ampules of gonadotropins, and days of stimulation with a modest decrease in pregnancy rates. The purpose of this analysis was to evaluate the relative cost differences per cycle and per pregnancy achieved by both methods of LH surge suppression.